CXCR4 and Miyoshi myopathy: Another 8 MM patients were then scheduled for CXCR4-directed RLT, and myeloma doses of up to 70 Gy were reported, with CR in 1 patient and PR in 5 subjects (overall survival, 7.5 mo).